Mechanisms of Selective Vulnerability in LBD and FTD (R01 Clinical Trial Not Allowed) | RFA NS 21 007

Opportunity Information: Apply for RFA NS 21 007

The National Institutes of Health (NIH) funding opportunity titled "Mechanisms of Selective Vulnerability in LBD and FTD (R01 Clinical Trial Not Allowed)" (Funding Opportunity Number RFA-NS-21-007) supports research projects aimed at explaining why abnormal dementia-related proteins build up in some parts of the brain but not others. In many neurodegenerative diseases, misfolded or aggregated proteins such as alpha-synuclein (commonly linked to Lewy body dementia, LBD) or tau (commonly implicated in several frontotemporal dementia, FTD, syndromes) do not spread evenly throughout the brain. Instead, they tend to accumulate in specific cell types, circuits, and brain regions, and this patterned vulnerability is believed to drive the distinct symptoms and clinical presentations that separate LBD from FTD and other dementias. The central goal of this announcement is to fund mechanistic studies that identify the biological reasons certain regions are selectively susceptible to abnormal protein deposition while other regions remain comparatively resistant.

This is an R01 grant mechanism, meaning it is intended for substantial, hypothesis-driven, research programs with clear aims, strong rationale, and rigorous experimental plans. The announcement explicitly indicates "Clinical Trial Not Allowed," signaling that applications should not propose clinical trials as defined by NIH policy. In practical terms, the emphasis is on foundational and translational research that investigates disease mechanisms rather than testing interventions in human participants via prospective, trial-like study designs. Projects could still involve human-derived materials (for example, postmortem tissue, biofluids, or patient-derived cell models) or observational analyses, as long as the work does not cross into clinical trial territory.

The scientific focus is the concept of selective regional vulnerability: the idea that specific neuronal populations or networks have intrinsic properties or environmental contexts that make them more likely to accumulate pathologic alpha-synuclein or tau, or more likely to be damaged by those aggregates once they appear. This opportunity is looking for studies that move beyond simply mapping where pathology occurs and instead explain the "why" and "how" behind those patterns. That could include investigating cell-type-specific biology, circuit connectivity that influences propagation, local immune or glial responses, differences in protein clearance pathways, metabolic stressors, synaptic activity patterns, gene expression programs that vary across regions, or structural and molecular features that make certain neurons more permissive to seeding and spread. The intended outcome is a clearer mechanistic framework for how regional patterns of pathology emerge in LBD and FTD, which in turn could point to more precise therapeutic targets or biomarkers tailored to the vulnerable systems in each disease.

From an administrative standpoint, the opportunity falls under the NIH discretionary grant category and is associated with CFDA numbers 93.853 and 93.866, reflecting NIH program areas relevant to neurological disorders and research. The original closing date listed for the opportunity is 2020-10-27, and the record shows a creation date of 2020-08-13. The listing does not provide an award ceiling or the expected number of awards, which sometimes means those details were either determined later, variable, or communicated through the full funding announcement documentation rather than the summarized record.

Eligibility is broad and includes many types of U.S. and non-U.S. organizations. Eligible applicants span state, county, city or township governments, special district governments, and independent school districts, as well as public and state-controlled institutions of higher education and private institutions of higher education. NIH also allows applications from federally recognized Native American tribal governments, as well as Native American tribal organizations that are not federally recognized tribal governments. Both nonprofit organizations (with or without 501(c)(3) status) and for-profit organizations (other than small businesses) may apply, along with small businesses and other entities. The announcement also highlights additional eligible applicant categories such as Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISI), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, eligible federal agencies, regional organizations, U.S. territories or possessions, and non-domestic (non-U.S.) entities, including foreign organizations. In effect, NIH is signaling an interest in attracting a wide range of capable research teams and institutional settings, including those that broaden geographic reach and support participation from diverse and underserved communities, while still focusing on high-impact mechanistic neuroscience.

Overall, the opportunity is designed to accelerate progress on a core challenge in neurodegeneration research: explaining the patterned, region-specific nature of alpha-synuclein and tau pathology in Lewy body dementia and frontotemporal dementia. By prioritizing mechanistic explanations for selective vulnerability at the level of cells, circuits, and regions, this R01 aims to deepen the field's understanding of why these diseases look the way they do clinically and biologically, and to lay groundwork for future strategies to prevent, slow, or redirect the processes that lead to regionally targeted brain degeneration.

• The National Institutes of Health in the health sector is offering a public funding opportunity titled "Mechanisms of Selective Vulnerability in LBD and FTD (R01 Clinical Trial Not Allowed)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.853, 93.866.
• This funding opportunity was created on 2020-08-13.
• Applicants must submit their applications by 2020-10-27. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.

Apply for RFA NS 21 007

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: